Get the Stockscreener App
0.5912
0.37%
0.0022
After Hours:
.61
0.0188
+3.18%
Cytosorbents Corp stock is traded at $0.5912, with a volume of 32,688.
It is up +0.37% in the last 24 hours and down -16.45% over the past month.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
See More
Previous Close:
$0.589
Open:
$0.61
24h Volume:
32,688
Relative Volume:
0.37
Market Cap:
$37.07M
Revenue:
$37.06M
Net Income/Loss:
$-8.20M
P/E Ratio:
-4.4351
EPS:
-0.1333
Net Cash Flow:
$-12.87M
1W Performance:
-4.66%
1M Performance:
-16.45%
6M Performance:
-35.46%
1Y Performance:
-41.47%
1-Day Range:
$0.58
$0.61
1-Week Range:
$0.5702
$0.621
52-Week Range:
$0.4992
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.5912 | 36.93M | 37.06M | -8.20M | -12.87M | -0.1333 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan
Cytosorbents granted 180-day extension by Nasdaq to meet minimum bid price - Investing.com South Africa
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan
Cytosorbents (CTSO) Takes Regulatory Gamble While Insiders Remain on the Sidelines and Institutions Are Divided - Bitget
CytoSorbents Corp (HQE1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Corp (HQE1.MU) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents Corporation 2025 Annual Report: Blood Purification Technologies, Clinical Trials, and Regulatory Insights - Minichart
Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed - TradingView
CytoSorbents (NASDAQ: CTSO) outlines global blood purification push and FDA path - Stock Titan
Cytosorbents’ Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents (CTSO) Q4 2025 Earnings Transcript - AOL.com
CytoSorbents 2025 Financials: Q4 & Annual Revenue and Loss ReportNews and Statistics - IndexBox
Cytosorbents Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral By Investing.com - Investing.com Canada
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral - Investing.com
CytoSorbents Reports 2025 Financial Results: Revenue Growth, Clinical Advances, and Path to Cash Flow Breakeven in 2026 - Minichart
CytoSorbents (CTSO) Reports Slight Revenue Increase and Strategi - GuruFocus
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Finviz
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... By GuruFocus - Investing.com Canada
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents reports Q4 2025 earnings miss, shares dip - Investing.com Australia
Cytosorbents Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cytosorbents (CTSO) Reports Record Sales Growth in 2025 - GuruFocus
CytoSorbents Corp (NASDAQ:CTSO) Reports Q4 2025 Earnings Miss, Stock Declines - chartmill.com
CytoSorbents: Q4 Earnings Snapshot - Barchart.com
CYTOSORBENTS ($CTSO) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Cytosorbents (CTSO) Expected to Announce Earnings on Monday - Defense World
If You Invested $1,000 in Cytosorbents Corp (CTSO) - Stock Titan
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Fidelity
Aug Drivers: How does Cytosorbents Corporation score in quality rankingsMarket Growth Summary & Safe Capital Growth Plans - baoquankhu1.vn
CytoSorbents Corp Stock (ISIN: US23283M1018) Faces Analyst Hold Amid Massive Upside Potential - AD HOC NEWS
Cytosorbents CorporationCommon Stock (Nasdaq:CTSO) Stock Quote - The Chronicle-Journal
CytoSorbents (CTSO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
CTSO PE Ratio & Valuation, Is CTSO Overvalued - Intellectia AI
Aug Fed Impact: Will Cytosorbents Corporation benefit from government policy2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - BioSpace
CTSO SEC FilingsCytosorbents Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Latest CTSO NewsCytoSorbents Announces the REFRESH 2-AKI Tr... - Stock Titan
CTSO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CTSO.O PE Ratio & Valuation, Is CTSO.O Overvalued - Intellectia AI
Travel Stocks: What makes Cytosorbents Corporation stock attractive today2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
Head to Head: Cytosorbents vs. Futureworld - National Today
Investment Report: Can Brookfield Business Partners LP Limited Partnership keep up with sector leadersInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance
Avenir reports 8.3% Cytosorbents (CTSO) ownership stake in 13G/A - Stock Titan
Aug Final Week: Is WaFd Inc stock undervalued right nowDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug PreEarnings: What makes Cytosorbents Corporation stock attractive today2025 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):